Literature DB >> 7516857

Gangliosides. Their role in clinical neurology.

E Nobile-Orazio1, M Carpo, G Scarlato.   

Abstract

Gangliosides are normal constituent of mammalian vertebrate cell membranes and are particularly abundant in the central and peripheral nervous systems. The biological effects of exogenously administered gangliosides have been extensively investigated in vitro and in experimental animal models where they have neuronotrophic and neuritogenic properties. Despite these findings there is still little evidence that treatment with parenteral gangliosides in humans can be effective in peripheral neuropathies or other neuromuscular diseases. The initial preliminary reports on the positive effects of GM1 in cerebrovascular diseases and spinal cord injury need to be confirmed in larger controlled trials. At the same time the occasional development of an acute motor neuropathy clinically presenting as the Guillain-Barré syndrome and associated with high titres of anti-ganglioside antibodies highlights the risks of their widespread use before more consistent data on their efficacy become available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516857     DOI: 10.2165/00003495-199447040-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  83 in total

1.  Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.

Authors:  J S Schneider; A Pope; K Simpson; J Taggart; M G Smith; L DiStefano
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

2.  Ganglioside inhibition of glutamate-mediated protein kinase C translocation in primary cultures of cerebellar neurons.

Authors:  F Vaccarino; A Guidotti; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Motoneuron-disease-like disorder after ganglioside therapy.

Authors:  N Yuki; S Sato; T Miyatake; K Sugiyama; T Katagiri; H Sasaki
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

4.  Gangliosides and their cell density-dependent changes in control and chemically transformed C3H/10T1/2 cells.

Authors:  R Langenbach; S Kennedy
Journal:  Exp Cell Res       Date:  1978-03-15       Impact factor: 3.905

5.  Effects of cerebral gangliosides in the alcoholic polyneuropathies.

Authors:  B Mamoli; G Brunner; R Mader; H Schanda
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

6.  GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug.

Authors:  C Argentino; M L Sacchetti; D Toni; G Savoini; E D'Arcangelo; F Erminio; F Federico; F F Milone; V Gallai; D Gambi
Journal:  Stroke       Date:  1989-09       Impact factor: 7.914

7.  Ganglioside and rabbit erythrocyte membrane receptor for staphylococcal alpha-toxin.

Authors:  I Kato; M Naiki
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

8.  Trial of ganglioside therapy for diabetic neuropathy.

Authors:  M Hallett; T Flood; N Slater; J Dambrosia
Journal:  Muscle Nerve       Date:  1987 Nov-Dec       Impact factor: 3.217

9.  Developmental changes in ganglioside composition and synthesis in embryonic rat brain.

Authors:  R K Yu; L J Macala; T Taki; H M Weinfield; F S Yu
Journal:  J Neurochem       Date:  1988-06       Impact factor: 5.372

10.  A double blind placebo controlled trial of mixed gangliosides in diabetic peripheral and autonomic neuropathy.

Authors:  R R Abraham; R M Abraham; V Wynn
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

View more
  7 in total

Review 1.  [Prehospital management of spinal cord injuries].

Authors:  M Bernhard; A Gries; P Kremer; A Martin-Villalba; B W Böttiger
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

Review 2.  GM1 Ganglioside: Past Studies and Future Potential.

Authors:  Massimo Aureli; Laura Mauri; Maria Grazia Ciampa; Alessandro Prinetti; Gino Toffano; Cynthia Secchieri; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2015-03-12       Impact factor: 5.590

Review 3.  Siglec receptors and hiding plaques in Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta
Journal:  J Mol Med (Berl)       Date:  2009-04-24       Impact factor: 4.599

4.  Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies.

Authors:  Jianshe Wei; Masayo Fujita; Masaaki Nakai; Masaaki Waragai; Akio Sekigawa; Shuei Sugama; Takato Takenouchi; Eliezer Masliah; Makoto Hashimoto
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

Review 5.  Role of sphingolipid metabolism in neurodegeneration.

Authors:  Manal Alaamery; Nour Albesher; Nora Aljawini; Moneera Alsuwailm; Salam Massadeh; Michael A Wheeler; Chun-Cheih Chao; Francisco J Quintana
Journal:  J Neurochem       Date:  2020-07-03       Impact factor: 5.546

Review 6.  Biomolecule-Functionalized Smart Polydiacetylene for Biomedical and Environmental Sensing.

Authors:  Eunae Cho; Seunho Jung
Journal:  Molecules       Date:  2018-01-04       Impact factor: 4.411

7.  Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke.

Authors:  Jun Zhong; Rong-Wei Li; Ju Wang; Ying Wang; Hong-Fei Ge; Ji-Shu Xian; Hua Feng; Liang Tan
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.